AIM ImmunoTech reports Q2 EPS (10c) vs. (10c) last year

As of June 30, AIM reported cash, cash equivalents and marketable securities of $28.4M, which management expects to fund operations through multiple key milestones through the end of 2024. “Over the course of the second quarter, our team continued to deliver on our timelines and made significant progress advancing Ampligen through our active human clinical studies in multiple indications. We continue to be encouraged by the growing body of positive and consistent data and believe Ampligen has the potential to be a meaningful treatment option across a number of high-value indications,” commented Thomas Equels, CEO. “Our operational execution remains supported by a strong cash position, and we are steadfast in our mission to advance the clinical development of our oncology pipeline, with pancreatic cancer as our lead development program. Looking ahead to the remainder of the year, we believe we are well-positioned to achieve a number of value-driving milestones.”